Jiang et al. observed that GRg3 enhances the anti-proliferative activity of erlotinib in pancreatic cancer cell lines by downregulating the EGFR/PI3K/Akt signaling pathway (Jiang et al., 2017). The gene discussed is AKT1; the disease is familial pancreatic carcinoma.